ERBB2 and neoplasm: In particular, 11/24 patients (45.8%), including 6/14 luminal A, 3/5 luminal B, and 2/4 HER2+ cases, showed an immunomodulatory response defined as a ≥10 percent increase in stromal TILs (sTILs) in tumor samples, and therefore they were considered responders.